Abbadessa, G.; Miele, G.; Cavalla, P.; Valentino, P.; Marfia, G.A.; Signoriello, E.; Landi, D.; Bosa, C.; Vercellino, M.; De Martino, A.;
et al. CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab. Int. J. Environ. Res. Public Health 2021, 18, 8163.
https://doi.org/10.3390/ijerph18158163
AMA Style
Abbadessa G, Miele G, Cavalla P, Valentino P, Marfia GA, Signoriello E, Landi D, Bosa C, Vercellino M, De Martino A,
et al. CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab. International Journal of Environmental Research and Public Health. 2021; 18(15):8163.
https://doi.org/10.3390/ijerph18158163
Chicago/Turabian Style
Abbadessa, Gianmarco, Giuseppina Miele, Paola Cavalla, Paola Valentino, Girolama Alessandra Marfia, Elisabetta Signoriello, Doriana Landi, Chiara Bosa, Marco Vercellino, Antonio De Martino,
and et al. 2021. "CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab" International Journal of Environmental Research and Public Health 18, no. 15: 8163.
https://doi.org/10.3390/ijerph18158163
APA Style
Abbadessa, G., Miele, G., Cavalla, P., Valentino, P., Marfia, G. A., Signoriello, E., Landi, D., Bosa, C., Vercellino, M., De Martino, A., Missione, R., Sparaco, M., Lavorgna, L., Lus, G., & Bonavita, S.
(2021). CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab. International Journal of Environmental Research and Public Health, 18(15), 8163.
https://doi.org/10.3390/ijerph18158163
